Roche Holding AG RHHBF
495.00 USD +6.53 (+1.34%)
At closeNov 9, 2026, 4:00 PM EST
490.00 Day range 490.00
351.11 52-week range 514.08
- YTD
- +11.09%
- 1 year
- +45.59%
- Market cap
- 394.40B
- EPS (ttm)
- 19.32
- P/E ratio
- 25.62
- YTD return
- +11.09%
- 1-year return
- +45.59%
- Volume
- 5
- Avg volume
- 92
- Open
- 490.00
- Previous close
- 488.47
- Day's range
- 490.00 – 490.00
- 52-week range
- 351.11 – 514.08
- Earnings date
- Jul 23, 2026
5D 0.00 (0.00%)
No chart data for this range yet.
Next earnings
Jul 23, 2026
Expected Jul 23, 2026. Consensus EPS estimate 12.51.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jul 23, 2026 | Jun 30, 2026 | 12.51 | — | — | — |
| Jan 29, 2026 | Dec 31, 2025 | 10.83 | 10.56 | -0.27 | -2.49% |
| Jul 24, 2025 | Jun 30, 2025 | 13.18 | 5.81 | -7.37 | -55.92% |
| Jan 30, 2025 | Dec 31, 2024 | 9.25 | 2.77 | -6.48 | -70.05% |
| Oct 23, 2024 | Jun 30, 2024 | 10.42 | 8.71 | -1.71 | -16.41% |
| Apr 26, 2024 | Dec 31, 2023 | 10.07 | 6.34 | -3.73 | -37.04% |
News
Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs 
Nurix Therapeutics Enrolls First Patient In Phase 1b/2 Study Of Bexobrutideg Plus Venetoclax In Chronic Lymphocytic Leukemia Under Roche Collaboration 
Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks 
Roche And Nurix Partner To Co-Develop BTK Degrader Bexobrutideg In $2.3B Deal Spanning Blood Cancers, Immunology And Neurology 
'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA - Stocks That Hit 52-Week Highs On Tuesday
Stocks That Hit 52-Week Highs On Tuesday 
Stocks That Hit 52-Week Highs On Friday - Stocks That Hit 52-Week Highs On Monday
- Stocks That Hit 52-Week Highs On Tuesday
Your note
Sign in to keep a note on RHHBF — it syncs with the Stock Master app.